US EditionPublished • loading... • Updated
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug candidate for Alzheimer’s disease. Buntanetap, previously developed in its original anhydrous form, has been used in all preclinical and clinical studies to date. The company’s researchers have now developed a dihydrate crystal form, which incorporates two mol…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
